Opioid petition could impact CME

Share this article:

By taking on “overly broad indications” on labels in a drug category that includes pain medications such as Purdue Pharma's Oxycontin and Endo Pharmaceutical's Percocet, a citizens' petition could regulate the way drugmakers market these products—and how CME programming about them is conducted.

The 37 signatories are asking the FDA to change the labels for prescription opioids to indicate that they are for severe pain, not for moderate-to-severe pain.

Dr. Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing, one  of the signatories, told MM&M that walling off what could be considered off-label uses would help doctors to walk away from CME programming about the medications “with a better sense of the risks vs. the benefits.”

These moves could also have a direct impact on promotion. Two of the-top 25 advertisers in professional media in 2011 were marketers with opioids in their pain portfolios. Purdue, 12th on the list according to data from Kantar Media, spent $8.8 million for ads in journals last year, while Endo, 23rd on the list, spent $4.4 million. Not all of this money went to promote pain medications, but modifying the labels of these drugs will have an impact on the million-dollar conversations that surround them.

"Many physicians were taught that addiction was extremely rare,” Kolodny said, “and we've found this extremely false.”

Neither Purdue nor Endo were available for comment.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?